Sunesis pharmaceuticals inc. (SNSS)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Revenue:
License and other revenue

2,073

237

669

-

-

-

-

-

-

-

-

Collaboration revenue

-

-

-

-

-

-

-

-

-

27

1,550

License and other revenue

-

-

-

2,536

3,061

5,734

7,956

3,754

5,000

6

2,212

Total revenues

-

-

-

2,536

3,061

5,734

7,956

3,754

5,000

33

3,762

Operating expenses:
Research and development

15,412

14,615

21,540

22,881

23,701

27,665

28,891

29,185

22,563

14,433

13,247

General and administrative

9,949

11,332

13,548

16,115

18,662

23,112

10,838

9,175

8,303

7,005

7,748

Restructuring charges

-

-

-

-

-

-

-

-

-

-

1,916

Total operating expenses

25,361

25,947

35,088

38,996

42,363

50,777

39,729

38,360

30,866

21,438

22,911

Loss from operations

-23,288

-25,710

-34,419

-36,460

-39,302

-45,043

-31,773

-34,606

-25,866

-21,405

-19,149

Interest expense

514

1,154

1,396

1,721

939

1,719

2,917

1,855

259

-

-

Other income, net

472

249

357

158

3,565

3,760

92

-7,490

5,984

-3,182

-21,077

Net loss

-23,330

-26,615

-35,458

-38,023

-36,676

-43,002

-34,598

-43,951

-20,141

-24,587

-40,226

Unrealized loss on available-for-sale securities

1

7

15

-

-

-

-

-

-

-

-

Unrealized gain on available-for-sale securities

-

-

-

-11

-4

-4

-41

19

34

-15

-8

Comprehensive loss

-23,329

-26,608

-35,443

-38,034

-36,680

-43,006

-34,639

-43,932

-20,107

-24,602

-40,234

Deemed distribution to preferred stockholders

-

-

-

-

-

-

-

-

-

-

27,563

Basic

-

-

-

-38,023

-36,676

-43,002

-34,598

-43,951

-

-

-67,789

Diluted

-

-

-

-38,023

-36,676

-46,894

-34,598

-43,951

-

-

-

Basic

-

-

-

15,688

12,156

10,010

52,249

48,146

-

-

-

Diluted

-

-

-

15,688

12,156

10,252

52,249

48,146

-

-

-

Basic

-

-

-

-2.42

-3.02

-4.30

-0.66

-0.91

-

-

-

Diluted

-

-

-

-2.42

-3.02

-4.57

-0.66

-0.91

-

-

-

Basic and diluted loss per common share:
Net loss

-23,330

-26,615

-35,458

-38,023

-36,676

-

-34,598

-43,951

-20,141

-24,587

-40,226

Shares used in computing net loss per common share

87,129

35,582

24,516

-

-

-

-

-

46,412

24,860

-

Net loss per common share

-0.27

-0.75

-1.45

-

-

-

-

-

-0.43

-0.99

-

Basic and diluted loss attributable to common stockholders per common share

-

-

-

-

-

-

-

-

-

-

-11.80